Adding a primate version of the monoclonal antibody Entyvio (vedolizumab, Takeda Pharmaceutical Co. Ltd.), which is approved for the treatment of ulcerative colitis and Crohn's disease, to combination antiretroviral therapy (ART) enabled macaque monkeys to control blood levels of SIV long after treatment with both the antibody and the ART had been discontinued.